Vidya Velagapudi

vidya velagapudi

Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

Director & Chair, National Metabolomics Core Facility,
Principal Investigator, Medicum, Faculty of Medicine,
Institute for Molecular Medicine FIMM, HiLIFE, University of Helsinki,
P.O Box-20, Helsinki-00014, Finland.
Website: https://www.fimm.fi/en/services/technology-centre/metabolomics

Vidya Velagapudi obtained her Bachelors in Bioscience (1999), Masters in Biotechnology (2001), Advanced PG diploma in Bioinformatics (2002), and then joined a Pharmaceutical company as a Research Associate (2002) in India. Later on she moved to Germany in 2003 for her graduate studies and obtained Ph.D in Applied Biochemistry from the University of Saarland in collaboration with the Max-Planck Institute for Informatics, Saarbrucken. Dr. Velagapudi then moved to VTT, Finland as a post-doctoral fellow in collaboration with University of Cambridge, UK, and continued as a Research Scientist and Project Manager during 2006-2009. Since 2010, Dr. Velagapudi has been leading the national Metabolomics core facility at the Institute for Molecular Medicine Finland (FIMM). Dr. Velagapudi is also affiliated to University of Helsinki (UH) as an Adjunct Professor (2012-) and Principal Investigator at the Faculty of Medicine (2016-), and Chair of Metabolomics Platforms in Biocenter Finland and HiLIFE (2017-). Dr. Velagapudi has published around 60 scientific articles in reputed journals and given over 30 invited talks in international scientific events and conferences. Dr. Velagapudi was an invited Metabolomics technology expert for an interview (2014) and spotlight article contributor (2016) at MetaboNews Letter, and international organising committee member for the Metabolomics Society 13th annual conference in Australia. Dr. Velagapudi is Finnish ambassador for ELIXIR Metabolomics community, a member of Metabolomics quality assurance and control consortium (mQACC), and an invited reviewer for H2020 proposals and core facilities.